Evidence map›Paper›PMID 29142990›Full record

ArticleKidney international reports2017

The Chemical Chaperone, PBA, Reduces ER Stress and Autophagy and Increases Collagen IV α5 Expression in Cultured Fibroblasts From Men With X-Linked Alport Syndrome and Missense Mutations.

Dongmao Wang, Mardhiah Mohammad, Yanyan Wang, Rachel Tan, Lydia S Murray, Sharon Ricardo, Hayat Dagher, Tom van Agtmael, Judy Savige

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Treatment Approaches for Alport Syndrome.Journal of the American Society of Nephrology : JASN · 2026
    Review
  4. Collagen IV in Gould syndrome and Alport syndrome.Nature reviews. Nephrology · 2025
    Review
  5. Genotype-Based Molecular Mechanisms in Alport Syndrome.Journal of the American Society of Nephrology : JASN · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Progress in therapeutic targets on podocyte for Alport syndrome.Journal of translational internal medicine · 2024
    Article
  12. Article
  13. Article
  14. Current and Future Therapeutical Options in Alport Syndrome.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Article
  17. Review
  18. Novel Therapies for Alport Syndrome.Frontiers in medicine · 2022
    Review
  19. Complexities of the glomerular basement membrane.Nature reviews. Nephrology · 2021
    Review
  20. Genetic Disorders of the Extracellular Matrix.Anatomical record (Hoboken, N.J. : 2007) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Dongmao WangThe University of Melbourne, Department of Medicine (Northern Health and Melbourne Health), Melbourne, Victoria, Australia.
Mardhiah MohammadThe University of Melbourne, Department of Medicine (Northern Health and Melbourne Health), Melbourne, Victoria, Australia.
Yanyan WangThe University of Melbourne, Department of Medicine (Northern Health and Melbourne Health), Melbourne, Victoria, Australia.
Rachel TanThe University of Melbourne, Department of Medicine (Northern Health and Melbourne Health), Melbourne, Victoria, Australia.
Lydia S MurrayInstitute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Sharon RicardoDepartment of Anatomy and Developmental Cell Biology, Monash University, Clayton, Victoria, Australia.
Hayat DagherThe University of Melbourne, Department of Medicine (Northern Health and Melbourne Health), Melbourne, Victoria, Australia.
Tom van AgtmaelInstitute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Judy SavigeThe University of Melbourne, Department of Medicine (Northern Health and Melbourne Health), Melbourne, Victoria, Australia.
Northern Health · AUUniversity of Glasgow · GBUniversity of Melbourne · AUMelbourne Health · AUMonash University · AU

Funding

Medical Research Council G0601268
6 · The paper itself

Abstract

introductionX-linked Alport syndrome (OMIM 301050) is caused by

methodsDermal fibroblast cultures were established from 2 affected men and 3 normals. Proliferation rates were examined, the collagen IV α5 chain localized with immunostaining, and levels of the intra- and extracellular chains quantitated with an in-house enzyme-linked immunosorbent assay.

resultsBoth DISCUSSION: Sodium 4-phenylbutyrate increases collagen IV α5 mRNA levels, reduces ER stress and autophagy, and possibly facilitates collagen IV α5 extracellular transport. Whether these actions delay end-stage renal failure in men with X-linked Alport syndrome and missense mutations will only be determined with clinical trials.

Indexed as

autophagychaperonesER stressmissense mutationsunfolded protein responseX-linked Alport syndrome

Identifiers

PMID29142990
PMCPMC5678609
OpenAlexW2601221906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.